Pedro Aleixo Nogueira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pedro Aleixo Nogueira has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Bianca Gomes Wanderley
Sírio-Libanês Hospital Department of Neurosurgery São Paulo, São Paulo
1 shared publication - Christopher Aquino Pereira Lima
Nove de Julho University (UNINOVE) School of Medicine São Bernardo do Campo, São Paulo
1 shared publication - Cleiton Formentin
Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil
1 shared publication - Giovana Clausson Bitolo
Universidade Nove de Julho, São Bernardo do Campo, São Paulo, Brasil
1 shared publication - Marcos Vinicius Calfat Maldaun
Teaching and Research Institute, Sírio-Libanês Hospital , São Paulo, São Paulo
1 shared publication - Mateus Dal Fabbro
Universidade Estadual de Campinas, Brazil
1 shared publication
Latest Publications
- 28 July 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
Prognosis of intracranial meningiomas with TERTp mutation: Systematic review with meta-analysis
Background: Telomerase reverse transcriptase promoter (TERTp; C228T/C250T) mutations are incorporated into the World Health Organization 2021 classification of meningiomas (20%-30% in grade 3) as criteria for higher-grade designation, despite heterogeneous evidence regarding their independent prognostic value. Objectives: To evaluate the association between TERTp mutations and overall survival (OS) and progression-free survival (PFS) in patients with intracranial meningiomas. Methods: A systematic review and meta-analysis of clinical-pathological cohort studies comparing TERTp-mutated and wild-type meningiomas was conducted. Studies were identified through searches of PubMed, Embase, and Web of Science. Survival outcomes were synthesized using hazard ratios (HRs) and median survival estimates. Results: Thirteen studies were included. Meta-analyses comprised 4 studies for PFS by HR, 5 for OS by HR, 5 for PFS by mean difference (MD) (8 comparisons), and 5 for OS by MD. Sensitivity analyses excluded Maas et al. (2021), Spiegl-Kreineck et al. (2018), and Mellai et al. (2021) from the PFS mean-difference, OS HR, and OS mean-difference models, respectively; no study was excluded from the PFS HR model. Conclusions: Telomerase reverse transcriptase promoter mutations identify a biologically aggressive meningioma subgroup with markedly reduced survival, supporting their role as prognostic biomarkers. However, their isolated use for tumor reclassification should be interpreted cautiously and integrated with additional molecular features. Registration: PROSPERO platform (No. CRD420251135452).
- 28 July 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
Prognosis of intracranial meningiomas with TERTp mutation: Systematic review with meta-analysis
Background: Telomerase reverse transcriptase promoter (TERTp; C228T/C250T) mutations are incorporated into the World Health Organization 2021 classification of meningiomas (20%-30% in grade 3) as criteria for higher-grade designation, despite heterogeneous evidence regarding their independent prognostic value. Objectives: To evaluate the association between TERTp mutations and overall survival (OS) and progression-free survival (PFS) in patients with intracranial meningiomas. Methods: A systematic review and meta-analysis of clinical-pathological cohort studies comparing TERTp-mutated and wild-type meningiomas was conducted. Studies were identified through searches of PubMed, Embase, and Web of Science. Survival outcomes were synthesized using hazard ratios (HRs) and median survival estimates. Results: Thirteen studies were included. Meta-analyses comprised 4 studies for PFS by HR, 5 for OS by HR, 5 for PFS by mean difference (MD) (8 comparisons), and 5 for OS by MD. Sensitivity analyses excluded Maas et al. (2021), Spiegl-Kreineck et al. (2018), and Mellai et al. (2021) from the PFS mean-difference, OS HR, and OS mean-difference models, respectively; no study was excluded from the PFS HR model. Conclusions: Telomerase reverse transcriptase promoter mutations identify a biologically aggressive meningioma subgroup with markedly reduced survival, supporting their role as prognostic biomarkers. However, their isolated use for tumor reclassification should be interpreted cautiously and integrated with additional molecular features. Registration: PROSPERO platform (No. CRD420251135452).